Skip to main content
  • Saved

made a Post

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies

Source :

https://link.springer.com/article/10.1007/s13300-020-00917-8

The growing epidemic of obesity and diabetes represents a growing health emergency, exemplified by a marked increase in cardiovascular and renal disease. As such, healthcare systems are increasingly focussing on therapeutic approaches to address these challenges. Cardiovascular outcome trials (CVOTs) evaluating glucagon-like peptide-1 (GLP-1) analogues have previously observed significant improvements in major adverse cardiac events in people with type 2 diabetes (T2D).